EUVIMEDSkopri EUVIMED
Crossref

Safety and Efficacy of Cangrelor in Acute Myocardial Infarction‐Related Cardiogenic Shock With and Without Cardiac Arrest

Wesley Bennar iD, Dorian Garin, Yuan Zhi, Chiara Schaffner, Thaïs Pittet, Adrian Attinger, Mario Togni, Florim Cuculi, Stephane Cook, Matthias Bossard, Diego Arroyo iD

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.70069 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2025. Written by Wesley Bennar and 10 co-authors. Institution: Department of Cardiology, University and Hospital Fribourg, Fribourg, Switzerland. Major MEDLINE topics: Shock, Cardiogenic, Adenosine Monophosphate, Platelet Aggregation Inhibitors, Heart Arrest. 28 references. Funded by: The study was supported by an unrestricted grant from the Fonds Scientifique Cardiovasculaire..

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Patients with acute myocardial infarction‐related cardiogenic shock (AMI‐CS) with and without cardiac arrest (CA) may experience delayed onset and absorption of oral P2Y12 inhibitors potentially leading to acute adverse events.

Aims

To assess the efficacy and safety of Cangrelor in AMI‐CS with and without CA, focusing on early stent thrombosis rates, bleeding events, and cardiovascular mortality.

Methods

A total of 168 patients treated with Cangrelor for AMI‐CS (Society for Cardiovascular Angiography & Interventions (SCAI)‐SHOCK stage C or higher) with and without CA were retrospectively included. Cangrelor administration protocol included a bolus of 30 μg/kg followed by an infusion of 4 μg/kg/min for 2−4 h.

Results

The mean age was 66.3 ± 11.4 years and 75.6% (127/168) were male. CA occurred in 60.7% (102/168) of patients, with a mean time to return of spontaneous circulation (ROSC) of 21.9 ± 24.3 min. The mean left ventricular ejection fraction (LVEF) was 33.2 ± 13.1%. No cases of acute stent thrombosis or reinfarction (< 48 h) were observed. In‐hospital mortality during index hospitalization occurred in 29.7% (49/168) of cases. Patients who presented with CA had a significantly higher mortality (36.3% vs. 13.6%, p = 0.002). Significant bleeding complications (BARC 3−5) were observed in 25.6% (43/168) of patients. The use of mechanical circulatory support (MCS) was significantly associated with more BARC 3‐5 bleeding (univariate OR 5.00; 95% CI 2.15 to 13.42; p < 0.001; multivariate p = 0.014). The mean cangrelor infusion dose was not linked to an increased bleeding risk (OR 1.00; 95% CI 1.00 to 1.00; p = 0.229). Preprocedural and discharge use of prasugrel, ticagrelor, or clopidogrel also showed no significant impact on BARC 3–5 bleeding (preprocedural p = 0.115, 0.223 and 0.831; discharge p = 0.455, 0.148 and 0.473, respectively). Following multivariate adjustment, the use of MCS, intensive care unit (ICU) duration, and reduced LVEF were the only predictors of bleeding risk ( p = 0.014, 0.010, and 0.042, respectively).

Conclusion

Cangrelor effectively prevents acute stent thrombosis and reinfarction within 48 h. Patients with MCS, longer ICU duration and reduced LVEF are at increased risk of bleeding complications. Cangrelor infusion duration per se was not associated with an increased risk of significant bleeding.

Subjects

MeSH terms (MEDLINE)

Shock, CardiogenicAdenosine MonophosphatePlatelet Aggregation InhibitorsHeart ArrestPercutaneous Coronary InterventionMyocardial InfarctionPurinergic P2Y Receptor AntagonistsHumansMaleFemaleAgedRetrospective StudiesTreatment OutcomeMiddle AgedTime FactorsHemorrhageRisk FactorsStentsVentricular Function, LeftReturn of Spontaneous CirculationRecovery of Function

Author keywords

antiplatelet therapycangrelorcardiac arrestcardiogenic shockmyocardial infarction

Substances

cangrelorAdenosine MonophosphatePlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Authors and institutions

  • Department of Cardiology, University and Hospital Fribourg, Fribourg, Switzerland.
  • Lucerne Cantonal Hospital, Lucerne, Switzerland.

ORCID profiles: Wesley Bennar, Diego Arroyo

Funding

  • The study was supported by an unrestricted grant from the Fonds Scientifique Cardiovasculaire.

Cite

APA

Bennar, W., Garin, D., Zhi, Y., Schaffner, C., Pittet, T., Attinger, A., Togni, M., Cuculi, F., Cook, S., Bossard, M., & Arroyo, D. (2025). Safety and Efficacy of Cangrelor in Acute Myocardial Infarction‐Related Cardiogenic Shock With and Without Cardiac Arrest. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70069

Vancouver

Bennar W, Garin D, Zhi Y, Schaffner C, Pittet T, Attinger A, et al. Safety and Efficacy of Cangrelor in Acute Myocardial Infarction‐Related Cardiogenic Shock With and Without Cardiac Arrest. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70069

BibTeX
@article{Bennar2025,
  author = {Bennar, Wesley and Garin, Dorian and Zhi, Yuan and Schaffner, Chiara and Pittet, Thaïs and Attinger, Adrian and Togni, Mario and Cuculi, Florim and Cook, Stephane and Bossard, Matthias and Arroyo, Diego},
  title = {Safety and Efficacy of Cangrelor in Acute Myocardial Infarction‐Related Cardiogenic Shock With and Without Cardiac Arrest},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.70069}
}
Start for free →